Cagrilintide is a synthetic long-acting amylin analog developed by Novo Nordisk. It activates amylin and calcitonin receptors and is most-studied as part of CagriSema, a fixed-dose combination with semaglutide currently in Phase 3 obesity trials. The proposed advantage is dual-pathway satiety signaling — amylin plus GLP-1 — rather than GLP-1 alone.
Research notes
How does Cagrilintide work?
Cagrilintide is a synthetic long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin from pancreatic beta cells; it slows gastric emptying and promotes satiety through a different receptor system than GLP-1 (specifically, the amylin and calcitonin receptors).
The compound is most-studied as part of CagriSema — a fixed-dose combination with semaglutide currently in Phase 3 obesity trials. The pairing combines amylin-receptor activation (cagrilintide) with GLP-1 receptor activation (semaglutide), targeting two complementary satiety pathways. Published Phase 2 data has shown weight-loss outcomes that exceed semaglutide alone, though direct comparison with tirzepatide is the open question.
Cagrilintide alone is studied less widely in research-protocol literature than the combination form. Most vendor catalog listings position it as a stack-with-semaglutide compound.
What doses are used in research?
The Phase 2 dose-escalation literature spans 0.16 mg → 4.5 mg weekly subcutaneous, with the higher doses producing the strongest weight-loss signal. Research-protocol references typically cite:
- 2.4 mg weekly as a mid-range maintenance dose
- 4.5 mg weekly as the upper end of published Phase 2 studies
- Cycled or escalated dosing — direct jumps to the higher dose produce more GI side effects
Half-life of approximately seven days supports weekly administration, matching the semaglutide schedule when the two are stacked.
What are the known side-effect concerns?
Reported side effects from Phase 2 trials cluster in the GLP-1-class-typical pattern:
- Nausea, vomiting, diarrhea — most common, dose-dependent, concentrated in titration
- Mild injection-site reactions at higher doses
- No distinct cardiovascular signal in published Phase 2 data, in contrast to retatrutide's heart-rate observation
What does this guide cover?
Public Janoshik testing data on cagrilintide is currently sparse — only one publicly-submitted test in our local mirror as of May 2026. As more vendors add the compound to their catalogs, the data layer below will populate. Until then, vendor audits for cagrilintide rely on identity confirmation alone; cross-vendor purity comparison isn't yet meaningful at this n.
What it's researched for
- weight management research
- amylin-analog studies
- GLP-1 combination protocols
Where to source it
ALL 2 VENDORS →2 audited vendors stock Cagrilintide, but the price walk hasn't captured a current listing for it. See all 2 vendors →
Frequently asked about Cagrilintide
What is cagrilintide?
Cagrilintide is a synthetic long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin from pancreatic beta cells; cagrilintide mimics its activity at the amylin and calcitonin receptors with a once-weekly dosing profile.
How does cagrilintide differ from semaglutide?
Semaglutide acts at the GLP-1 receptor; cagrilintide acts at amylin and calcitonin receptors. The two compounds target complementary satiety pathways, which is why they are most-studied together as CagriSema rather than as standalone obesity treatments.
What is CagriSema?
CagriSema is the fixed-dose combination of cagrilintide and semaglutide currently in Phase 3 obesity trials. Phase 2 data has shown weight-loss outcomes that exceed semaglutide alone; head-to-head comparison against tirzepatide is the open commercial question.
Is cagrilintide FDA-approved?
No. Cagrilintide is in Phase 3 development as part of CagriSema and is not approved by the FDA, EMA, or any regulator as a standalone or combination drug. It is sold only as research-grade material.
What doses are used in cagrilintide research?
Published Phase 2 dose-escalation studies tested 0.16 mg up to 4.5 mg weekly subcutaneous. The compound has a half-life of approximately 7 days, which is why weekly dosing dominates the published protocols.